Clinical trial · Observational
Prognostic Value of Vitamin D Levels in Egyptian Females With Breast Cancer
NCT03594214CI-TRIAL-00049982unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In our study; we aim to analyze the correlation between pre-treatment serum vitamin D (VD) levels and breast cancer prognostic features in newly diagnosed breast cancer patients presenting to our department.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Vitamin D Deficiency | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| serum vitamin d level measured by ELISA kit | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Single arm
- description
- pre-treatment serum vitamin d level measured by ELISA kit in patients confirmed for diagnosis with invasive breast cancer and before receiving any treatment for breast cancer
- interventionNames
- Diagnostic Test: serum vitamin d level measured by ELISA kit
Primary outcomes (1)
- measure
- Correlation of vitamin D levels with prognostic features
- timeFrame
- 2 years
- description
- Analysis of the correlation between; pre-treatment serum vitamin D levels, and breast cancer prognostic features.
Secondary outcomes (1)
- measure
- Correlation of vitamin d levels with treatment outcomes
- timeFrame
- 5 years
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Female patients * Newly diagnosed breast cancer patients. * Histologically confirmed invasive breast carcinoma (IBC) * Non- metastatic. * Treatment naïve patients. * Age: ≥18 and older * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. * Patients must have normal organ function as regards LFTs and RFTs Exclusion Criteria: * Male patients * Metastatic patients * Previous history of breast cancer diagnosis or treatment * Kidney impairment or renal stones * History of parathyroidectomy * Hypercalcemia, defined as serum level \>11 mg/dl. * Abnormal laboratory data for: AST (SGOT), ALT (SGPT), Serum Bilirubin, Alkaline phosphatase, Creatinine and/or Creatinine clearance, and Albumin. * Female patients who are pregnant or breast feeding. * Patients already on treatment or previously treated for vitamin D defeciency
References
Publications (2)
- BACKGROUNDde Sousa Almeida-Filho B, De Luca Vespoli H, Pessoa EC, Machado M, Nahas-Neto J, Nahas EAP. Vitamin D deficiency is associated with poor breast cancer prognostic features in postmenopausal women. J Steroid Biochem Mol Biol. 2017 Nov;174:284-289. doi: 10.1016/j.jsbmb.2017.10.009. Epub 2017 Oct 12. PMID 29031688
- BACKGROUNDIsmail A, El-Awady R, Mohamed G, Hussein M, Ramadan SS. Prognostic Significance of Serum Vitamin D Levels in Egyptian Females with Breast Cancer. Asian Pac J Cancer Prev. 2018 Feb 26;19(2):571-576. doi: 10.22034/APJCP.2018.19.2.571. PMID 29481024